MICROBIOLOGY PPT LECTURE NOTES | Karya Tulis Ilmiah
Corynebacterium diphtheriae
Biological
Features
Aerobic,
Gram+, Noncapsulated, rods
Gray-black colonies on tellurite 亚碲酸盐 medium
Metachromatic granules
Chinese-letter morphology in Gram stain
Transmission and Risk fact
solely
ors
among humans
spread by droplets
secretions
direct contact
Poor
nutrition
Crowded or unsanitary
living conditions
Low vaccine coverage
among infants and
children
Immunity gaps in
adults
Pathogenesis of diphtheria
Early
stages: Sore throat. Low fever. Swollen
neck glands.
Late stages: Airway obstruction and breathing
difficulty. Shock
Diphtheria Toxin
(DT)
Cleaved to yield A/B fragment, joined by S-S bond
- A (catalytic domain)
- B (transmembrane and receptor binding domains)
Receptor: heparin-binding epidermal growth factor - rich on cardiac cells and nerve cells
Toxin diffuses throughout body via blood
- Cardiac, neurologic complications
- Heart/respiratory damage, paralysis
Thick
grey
‘pseudomembrane’
composed of fibrin,
epithelial cells,
bacteria and
polymorph
neutrophils
Pseudomembrane
may cause blockage,
suffocation
The cervical lymph nodes enlarge causing oedema
of the neck (a classical condition of ‘bullneck’
bullneck’)
Epidemiology
Largely controlled
However,
now by vaccination
factors such as poverty and other
social factors have led to diphtheria being an
endemic/epidemic in many regions of the
world
Immunity
Immunization
of animals with altered toxin, pr
oducing antitoxin, was first done in 1890, 1st
used in humans in 1891
Toxin-antitoxin introduced by Theobald Smit
h in 1909, used little
Toxoid introduced in 1923, now widely used
Schick test
Be
used to ascertain population risk
This test involves the injection of a minute amount of
the diphtheria toxin under the skin. The absence of a reaction
indicates immunity.
DIAGNOSIS
Clinical:
Muscle weakness, edema and a pseu
domembranous material in the upper respirator
y tract characterizes diphtheria.
Laboratory: Tellurite media is the agar of cho
ice for isolation of Corynebacteria, which prod
uce jet black colonies
Control
Sanitary: Reduce carrier rate by use of vac
cine.
Immunological: A vaccine (DPT) prepare
d from an alkaline formaldehyde inactivated t
oxin (i.e. toxoid) is required. Passive immuni
zation with antitoxin can be used for patients.
Chemotherapeutic: Penicillin, erythromy
cin or gentamicin are drugs of choice.
Prospect
For therapy of tumors !
!
tumor
Ab
DT
Biological
Features
Aerobic,
Gram+, Noncapsulated, rods
Gray-black colonies on tellurite 亚碲酸盐 medium
Metachromatic granules
Chinese-letter morphology in Gram stain
Transmission and Risk fact
solely
ors
among humans
spread by droplets
secretions
direct contact
Poor
nutrition
Crowded or unsanitary
living conditions
Low vaccine coverage
among infants and
children
Immunity gaps in
adults
Pathogenesis of diphtheria
Early
stages: Sore throat. Low fever. Swollen
neck glands.
Late stages: Airway obstruction and breathing
difficulty. Shock
Diphtheria Toxin
(DT)
Cleaved to yield A/B fragment, joined by S-S bond
- A (catalytic domain)
- B (transmembrane and receptor binding domains)
Receptor: heparin-binding epidermal growth factor - rich on cardiac cells and nerve cells
Toxin diffuses throughout body via blood
- Cardiac, neurologic complications
- Heart/respiratory damage, paralysis
Thick
grey
‘pseudomembrane’
composed of fibrin,
epithelial cells,
bacteria and
polymorph
neutrophils
Pseudomembrane
may cause blockage,
suffocation
The cervical lymph nodes enlarge causing oedema
of the neck (a classical condition of ‘bullneck’
bullneck’)
Epidemiology
Largely controlled
However,
now by vaccination
factors such as poverty and other
social factors have led to diphtheria being an
endemic/epidemic in many regions of the
world
Immunity
Immunization
of animals with altered toxin, pr
oducing antitoxin, was first done in 1890, 1st
used in humans in 1891
Toxin-antitoxin introduced by Theobald Smit
h in 1909, used little
Toxoid introduced in 1923, now widely used
Schick test
Be
used to ascertain population risk
This test involves the injection of a minute amount of
the diphtheria toxin under the skin. The absence of a reaction
indicates immunity.
DIAGNOSIS
Clinical:
Muscle weakness, edema and a pseu
domembranous material in the upper respirator
y tract characterizes diphtheria.
Laboratory: Tellurite media is the agar of cho
ice for isolation of Corynebacteria, which prod
uce jet black colonies
Control
Sanitary: Reduce carrier rate by use of vac
cine.
Immunological: A vaccine (DPT) prepare
d from an alkaline formaldehyde inactivated t
oxin (i.e. toxoid) is required. Passive immuni
zation with antitoxin can be used for patients.
Chemotherapeutic: Penicillin, erythromy
cin or gentamicin are drugs of choice.
Prospect
For therapy of tumors !
!
tumor
Ab
DT